Everything biobased: plastic, medicine, and fuel. It seems like a futuristic utopia. But for how long? A collaboration of researchers now proposes an idea to accelerate the development process. By ...

The U.S. has been adept at inventing The Next Big Thing, but sometimes stumbles when it comes to exploiting it. From cars to electronics, solar panels, and semiconductors, this pattern has been ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

IBB is iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index. In the last three years, IBB has remained flat and significantly underperformed the S&P 500. For retail investors, we think ...

In 2025, fewer biotech deals are getting done, but the dollars behind them are bigger than ever. Having spent years working with emerging and fast-growth life sciences companies, I’ve seen firsthand ...

Accra, July 02, GNA-The International Service for the Acquisition of Agri-biotech Applications (ISAAA AfriCenter) in collaboration with its partners has launched a continental digital portal designed ...

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment ...

Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...